A significant driver of top-line growth: Crinetics Pharmaceuticals Inc (CRNX)

With 1.09 million shares changed hands, the volume of the stock remained heavier than its average volume of 0.76 million shares. The 52-week range on CRNX shows that it touched its highest point at $47.58 and its lowest point at $15.36 during that stretch. It currently has a 1-year price target of $57.14. Beta for the stock currently stands at 0.63.

Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.

Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!

Get the FREE Report with all the details here.


Sponsored

Price Performance and Earnings:

Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of CRNX was up-trending over the past week, with a rise of 5.06%, but this was up by 13.65% over a month. Three-month performance surged to 30.15% while six-month performance rose 58.59%. The stock gained 191.91% in the past year, while it has gained 30.78% so far this year. A look at the trailing 12-month EPS for CRNX yields -3.70 with Next year EPS estimates of -3.54. For the next quarter, that number is -0.81. This implies an EPS growth rate of 13.21% for this year and -10.42% for next year.

Float and Shares Shorts:

At present, 77.93 million CRNX shares are outstanding with a float of 71.18 million shares on hand for trading. On Mar 15, 2024, short shares totaled 5.01 million, which was 6.43% higher than short shares on Feb 15, 2024. In addition to CROX as the firm’s Crocs, Inc., CRNC serves as its Cerence Inc.

Institutional Ownership:

Through their ownership of 97.38% of CRNX’s outstanding shares, institutional investors have majority control over the company.

Analysts Ratings:

Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for CRNX since 0 analysts follow the stock currently. In the same way, a target price assigned to a stock can also reveal much about its potential.

Dividends & Yield:

In terms of dividends, CRNX has a current ratio of $––, which is $–– over the trailing 12-months, while a dividend of $–– is likely to be paid on average over the next five years. Dividend yield is another indicator that appeals to many investors, and CRNX currently yields $0.00. In the past year, CRNX’s dividend yield has been $0.00, but when looking at the stock over the past five years, its yield has been $–. Accordingly, CRNX has a current buyback yield of $––. This was $–– for the TTM, and it was $–– for the past five years.